Research programme: pain therapeutics - Jubilant Biosys/Orion Corporation
Latest Information Update: 16 May 2014
At a glance
- Originator Jubilant Biosys; Orion
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Pain
Most Recent Events
- 13 May 2014 Early research in Pain in USA and India (unspecified route)